Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
2 files | 1.85 MB
Add to list
  1. Search results
  2. Minimal adherence threshold to non-vi...

Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study

Maxim Grymonprez, Stephane Steurbaut, Andreas Capiau (UGent) , Delphine Vauterin (UGent) , Frauke Van Vaerenbergh (UGent) , Els Mehuys (UGent) , Koen Boussery (UGent) , Tine De Backer (UGent) and Lies Lahousse (UGent)
(2025) CARDIOVASCULAR DRUGS AND THERAPY. 39(1). p.107-117
Author
Organization
Project
Abstract
Purpose Poor adherence to non-vitamin K antagonist oral anticoagulants (NOACs) may raise thromboembolic risks in patients with atrial fibrillation (AF). However, the minimal adherence to maintain the protective effect of NOACs is currently unknown. Therefore, we investigated thresholds of NOAC adherence in association with thromboembolic and mortality risks.Methods Patients with AF initiating NOACs between 2013 and 2019 were identified in Belgian nationwide data. Adherence was measured using the proportion of days covered (PDC) after one year of treatment. Inverse probability of treatment weighted Cox regression was used to investigate outcomes.Results 92,111 persons were included (250,750 person-years). Compared to NOAC users with a one-year PDC of 100%, significantly higher risks of stroke or systemic embolism were observed among NOAC users with PDCs of 85-89% (adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI) (1.19-1.54)), 80-84% (aHR 1.31, 95%CI (1.08-1.58)) and < 80% (aHR 1.64, 95%CI (1.34-2.01)), while no significant differences were observed among NOAC users with one-year PDCs of 95-99% (aHR 1.02, 95%CI (0.94-1.12)) or 90-94% (aHR 1.06, 95%CI (0.95-1.18)). Significantly higher risks of all-cause mortality were observed with decreasing levels of NOAC adherence, which were already higher among NOAC users with a one-year PDC of 90-94% versus 100% (aHR 1.09, 95%CI (1.01-1.17)). Findings were similar with once-daily and twice-daily dosed NOACs.Conclusion Poor adherence to NOACs is associated with increased risks of thromboembolism and all-cause mortality. The minimal adherence threshold should be & GE; 90%, preferably even & GE; 95%.
Keywords
Atrial fibrillation, NOAC, adherence, thromboembolism, mortality, OUTCOMES, IMPACT, INTERRUPTION, WARFARIN, THERAPY, STROKE

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.54 MB
  • Download
    Grymonprez M et al Accepted Manuscript.docx
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • Word
    • |
    • 310.12 KB

Citation

Please use this url to cite or link to this publication:

MLA
Grymonprez, Maxim, et al. “Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death : A Nationwide Cohort Study.” CARDIOVASCULAR DRUGS AND THERAPY, vol. 39, no. 1, 2025, pp. 107–17, doi:10.1007/s10557-023-07507-3.
APA
Grymonprez, M., Steurbaut, S., Capiau, A., Vauterin, D., Van Vaerenbergh, F., Mehuys, E., … Lahousse, L. (2025). Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study. CARDIOVASCULAR DRUGS AND THERAPY, 39(1), 107–117. https://doi.org/10.1007/s10557-023-07507-3
Chicago author-date
Grymonprez, Maxim, Stephane Steurbaut, Andreas Capiau, Delphine Vauterin, Frauke Van Vaerenbergh, Els Mehuys, Koen Boussery, Tine De Backer, and Lies Lahousse. 2025. “Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death : A Nationwide Cohort Study.” CARDIOVASCULAR DRUGS AND THERAPY 39 (1): 107–17. https://doi.org/10.1007/s10557-023-07507-3.
Chicago author-date (all authors)
Grymonprez, Maxim, Stephane Steurbaut, Andreas Capiau, Delphine Vauterin, Frauke Van Vaerenbergh, Els Mehuys, Koen Boussery, Tine De Backer, and Lies Lahousse. 2025. “Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death : A Nationwide Cohort Study.” CARDIOVASCULAR DRUGS AND THERAPY 39 (1): 107–117. doi:10.1007/s10557-023-07507-3.
Vancouver
1.
Grymonprez M, Steurbaut S, Capiau A, Vauterin D, Van Vaerenbergh F, Mehuys E, et al. Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study. CARDIOVASCULAR DRUGS AND THERAPY. 2025;39(1):107–17.
IEEE
[1]
M. Grymonprez et al., “Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study,” CARDIOVASCULAR DRUGS AND THERAPY, vol. 39, no. 1, pp. 107–117, 2025.
@article{01HX6M4DQE6DX3TT1XHY5FE690,
  abstract     = {{Purpose Poor adherence to non-vitamin K antagonist oral anticoagulants (NOACs) may raise thromboembolic risks in patients with atrial fibrillation (AF). However, the minimal adherence to maintain the protective effect of NOACs is currently unknown. Therefore, we investigated thresholds of NOAC adherence in association with thromboembolic and mortality risks.Methods Patients with AF initiating NOACs between 2013 and 2019 were identified in Belgian nationwide data. Adherence was measured using the proportion of days covered (PDC) after one year of treatment. Inverse probability of treatment weighted Cox regression was used to investigate outcomes.Results 92,111 persons were included (250,750 person-years). Compared to NOAC users with a one-year PDC of 100%, significantly higher risks of stroke or systemic embolism were observed among NOAC users with PDCs of 85-89% (adjusted hazard ratio (aHR) 1.35, 95% confidence interval (CI) (1.19-1.54)), 80-84% (aHR 1.31, 95%CI (1.08-1.58)) and < 80% (aHR 1.64, 95%CI (1.34-2.01)), while no significant differences were observed among NOAC users with one-year PDCs of 95-99% (aHR 1.02, 95%CI (0.94-1.12)) or 90-94% (aHR 1.06, 95%CI (0.95-1.18)). Significantly higher risks of all-cause mortality were observed with decreasing levels of NOAC adherence, which were already higher among NOAC users with a one-year PDC of 90-94% versus 100% (aHR 1.09, 95%CI (1.01-1.17)). Findings were similar with once-daily and twice-daily dosed NOACs.Conclusion Poor adherence to NOACs is associated with increased risks of thromboembolism and all-cause mortality. The minimal adherence threshold should be & GE; 90%, preferably even & GE; 95%.}},
  author       = {{Grymonprez, Maxim and Steurbaut, Stephane and Capiau, Andreas and Vauterin, Delphine and Van Vaerenbergh, Frauke and Mehuys, Els and Boussery, Koen and De Backer, Tine and Lahousse, Lies}},
  issn         = {{0920-3206}},
  journal      = {{CARDIOVASCULAR DRUGS AND THERAPY}},
  keywords     = {{Atrial fibrillation,NOAC,adherence,thromboembolism,mortality,OUTCOMES,IMPACT,INTERRUPTION,WARFARIN,THERAPY,STROKE}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{107--117}},
  title        = {{Minimal adherence threshold to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation to reduce the risk of thromboembolism and death : a nationwide cohort study}},
  url          = {{http://doi.org/10.1007/s10557-023-07507-3}},
  volume       = {{39}},
  year         = {{2025}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: